인종/민족별약물반응

Abacavir

연관된 유전자

유전자 정보	유전자 (Gene)	유전형 (Genotype)	표현형 (Phenotype)	근거 수준* (관련 항목)	참고문헌 (Reference)
유전자 정보	HLA-B	*57:01	-	1A (부작용)	Whirl-Carrillo M, et al. Clin Pharmcol Ther (2012, PMID:22992668) JM Barbarino, et al. Pharmacogenet Genomics (2014, PMID:24625462)
약물대사 및 수송

사용된 이미지는 PharmGKB에서 제공하는 Pathway diagram을 이용하였습니다.
PharmGKB(pharmgkb.org) 사이트 보기

약력학에 대한 유전적 영향

지표 (Outcome)	유전자 (Gene)	유전형 (Genotype)	인종 (Ethnic group)	Treatment	n	환자군 (Subjects)	결과 (Results)	참고문헌 (Reference)
Abacavir hypersensitivity (ABH)	HLA-B	*57:01	Mixed population	1) Abacavir	20/468	HIV-1 patients	ABH incidence 57:01 positive: 90% (n=18/20) 57:01 negative: 0% (n=0/468) OR=6,934 (95% CI=321149,035, p <0.001)	1) Berka N, et al. Hum Immunol (2012, PMID:22197535) 2) Munderi P, et al. Trop Med Int Health (2011, PMID: 21091860) 3) Tangamornsuksan W, et al. J Pharm Pharm Sci (2015, PMID: 25877443) 4) Sousa-Pinto B, et al. J Allergy Clin Immunol (2015, PMID: 25934581) 5) Baniasadi S, et al. Tanaffos (2016, PMID: 27403179)
			Asian	3) Abacavir	1/231	patients received abacavir	Clinical manifestation 57:01 positive: 100% (n=1/1) 57:01 negative: 7.44% (n=16/231) OR=39.18 (95% CI=1.54-999.9)
			Caucasian	3) Abacavir	169/1,179	patients received abacavir	Clinical manifestation 57:01 positive: 80.47% (n=136/169) 57:01 negative: 13.06% (n=154/1,179) OR=24.31 (95% CI=14.8639.1, p =0.390)
			Caucasian	3) Abacavir	140/1,598	patients received abacavir	Immunologic confirmation 57:01 positive: 72.14% (n=101/140) 57:01 negative: 0.2% (n=3/1,598) OR=1,112.96 (95% CI=319.65-3,875.11, p =0.428)
			Black	2) Abacavir	247	patients received abacavir	Ugandan population의 Abacavir hypersensivity를 나타낸 case 중 HLA-B*5701을 가지는 경우가 없었다. 다른 HLA-B marker도 abacavir hypersensitivity와 유의한 연관성이 없었다.
			Black	3) Abacavir	13/674	patients received abacavir	Clinical manifestation 57:01 positive: 84.62% (n=11/13) 57:01 negative: 12.02% (n=81/674) OR=22.81 (95% CI= 5.61-92.73, p =0.390)
			Black	3) Abacavir	14/326	patients received abacavir	Immunologic confirmation 57:01 positive: 42.86% (n=6/14) 57:01 negative: 0% (n=0/326) OR=851.62 (95% CI=67.89-10,682.31, p =0.953)
			Iranian	5) Abacavir	1	HIV positive patients	57:01 positive: n=1 57:01 negative: n=0
			Other	3) Abacavir	1	patients received abacavir	Clinical manifestation 57:01 positive: 100% (n=1/1) 57:01 negative: 37.5% (n=9/24) OR=23.64 (95% CI=15.39-36.3, p =0.6520)
ABH diagnosis			Mixed population	4) Abacavir		HIV patients	Broad clinical diagnosis criteria OR=32.12 (95% CI=22.21-46.44, p <0.001) Strict clinical diagnosis criteria OR=177.71 (95% CI=48.44-651.96, p <0.001) Immunological criteria OR=859.13 (95% CI=189.19-3901.37, p <0.001)
			Mixed population (including both African Americans and African populations)	4) Abacavir		HIV patients	Clinical diagnosis criteria OR=11.1 (95% CI=3.78-32.63, p < 0.001)
			Caucasian	4) Abacavir	400	HIV patients	Clinical diagnosis criteria OR=31.92 (95% Cl=21.67-47.02, p <0.001) Immunological criteria OR=1,507.01 (95% Cl=200.78-11,311.25, p <0.001)
			Africans and individuals of African Descent	4) Abacavir		HIV patients	Clinical diagnosis criteria OR=11.10 (95% Cl=3.78-32.63) Immunological criteria OR=899.80 (95% Cl=38.47-21,045.27)
			Hispanics	4) Abacavir			Clinical diagnosis criteria OR=17.58 (95% Cl=3.85-80.37, p <0.001)
	Comments	ABH diagnosis를 broad clinical criteria를 이용한 경우보다 strich clinical criteria 혹은 skin patch test를 이용한 경우에 HLA-B*5701 allele와 abacavir hypersenitivity와 유의한 연관성이 있었다.

등록일 : 2020-12-04